Patients were randomised in a 1:1 ratio to receive oral treatment with 400 mg raltegravir twice daily plus 800 mg darunavir and 100 mg ritonavir once daily ( NtRTI-sparing regimen ) or tenofovir-emtricitabine in a 245 mg and 200 mg fixed-dose combination once daily , plus 800 mg darunavir and 100 mg ritonavir once daily ( standard regimen ) .